Skip to main content

Table 5 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) vs. other diseases (inflammatory and non-inflammatory) of the CNS (INF and N-INF) after data reduction with PCA.

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

  Disease Predicted Group Membershipb.c Total
RRMS INF and N-INF
Original
 Count RRMS 55 14 69
INF and N-INF 11 58 69
 % RRMS 79.7 20.3 100
INF and N-INF 15.9 84.1 100
Cross-validateda
 Count RRMS 55 14 69
INF and N-INF 11 58 69
 % RRMS 79.7 20.3 100
INF and N-INF 15.9 84.1 100
  1. aCross-validation is done only for those sets of samples analyzed. In cross-validation, each sample is classified by the functions derived from all samples other the one under analysis
  2. b81.9% of original grouped samples correctly classified
  3. c81.9% of cross-validated grouped samples correctly classified